ScandiDos AB (publ) (SDOS.ST)
SEK 1.64
(-1.2%)
SEK 1.64
(-1.2%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.48 Million SEK | -63.76% |
| 2022 | -8.22 Million SEK | -7.99% |
| 2021 | -7.61 Million SEK | -2070.66% |
| 2020 | -351 Thousand SEK | 97.28% |
| 2019 | -12.91 Million SEK | 26.42% |
| 2018 | -17.54 Million SEK | -50.53% |
| 2017 | -11.65 Million SEK | 7.32% |
| 2016 | -12.57 Million SEK | 6.99% |
| 2015 | -13.52 Million SEK | 12.33% |
| 2014 | -15.42 Million SEK | -334.06% |
| 2013 | -3.55 Million SEK | -167.95% |
| 2012 | -1.32 Million SEK | -336.79% |
| 2011 | 560 Thousand SEK | -61.14% |
| 2010 | 1.44 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -388 Thousand SEK | 95.04% |
| 2023 Q1 | -5.51 Million SEK | -299.24% |
| 2023 FY | -13.47 Million SEK | -63.76% |
| 2023 Q4 | -7.83 Million SEK | -963.29% |
| 2023 Q3 | 907 Thousand SEK | 187.46% |
| 2023 Q2 | -1.03 Million SEK | 81.2% |
| 2022 Q4 | 2.76 Million SEK | 264.72% |
| 2022 Q1 | -7.08 Million SEK | -301.64% |
| 2022 FY | -8.22 Million SEK | -7.99% |
| 2022 Q2 | -2.23 Million SEK | 68.51% |
| 2022 Q3 | -1.68 Million SEK | 24.65% |
| 2021 Q2 | -1.69 Million SEK | 45.95% |
| 2021 Q4 | -1.76 Million SEK | -71.76% |
| 2021 FY | -7.61 Million SEK | -2070.66% |
| 2021 Q1 | -3.13 Million SEK | -384.39% |
| 2021 Q3 | -1.02 Million SEK | 39.37% |
| 2020 Q3 | -634 Thousand SEK | -149.73% |
| 2020 Q4 | -647 Thousand SEK | -2.05% |
| 2020 FY | -351 Thousand SEK | 97.28% |
| 2020 Q1 | -345 Thousand SEK | 90.95% |
| 2020 Q2 | 1.27 Million SEK | 469.57% |
| 2019 Q4 | -3.81 Million SEK | -160.7% |
| 2019 Q3 | -1.46 Million SEK | 63.51% |
| 2019 FY | -12.91 Million SEK | 26.42% |
| 2019 Q1 | -3.62 Million SEK | -1971.43% |
| 2019 Q2 | -4 Million SEK | -10.59% |
| 2018 Q3 | -2.26 Million SEK | 64.5% |
| 2018 Q4 | -175 Thousand SEK | 92.26% |
| 2018 FY | -17.54 Million SEK | -50.53% |
| 2018 Q2 | -6.36 Million SEK | 27.18% |
| 2018 Q1 | -8.74 Million SEK | -1182.11% |
| 2017 Q4 | -682 Thousand SEK | 77.11% |
| 2017 FY | -11.65 Million SEK | 7.32% |
| 2017 Q1 | -4.58 Million SEK | -69.23% |
| 2017 Q2 | -3.4 Million SEK | 25.67% |
| 2017 Q3 | -2.97 Million SEK | 12.61% |
| 2016 Q1 | -5.23 Million SEK | -21.12% |
| 2016 FY | -12.57 Million SEK | 6.99% |
| 2016 Q4 | -2.71 Million SEK | -26.16% |
| 2016 Q3 | -2.14 Million SEK | 13.67% |
| 2016 Q2 | -2.48 Million SEK | 52.43% |
| 2015 Q1 | -6.51 Million SEK | -25.03% |
| 2015 Q4 | -4.31 Million SEK | -180.94% |
| 2015 Q2 | -1.14 Million SEK | 82.41% |
| 2015 Q3 | -1.53 Million SEK | -34.0% |
| 2015 FY | -13.52 Million SEK | 12.33% |
| 2014 FY | -15.42 Million SEK | -334.06% |
| 2014 Q4 | -5.21 Million SEK | -262.33% |
| 2014 Q2 | -3.48 Million SEK | 33.92% |
| 2014 Q1 | -5.28 Million SEK | -84.04% |
| 2014 Q3 | -1.43 Million SEK | 58.76% |
| 2013 Q4 | -2.86 Million SEK | -368.38% |
| 2013 FY | -3.55 Million SEK | -167.95% |
| 2013 Q1 | -1 Million SEK | -308.07% |
| 2013 Q2 | -748 Thousand SEK | 25.57% |
| 2013 Q3 | 1.06 Million SEK | 242.91% |
| 2012 Q4 | 483 Thousand SEK | 131.02% |
| 2012 Q3 | -1.55 Million SEK | 0.0% |
| 2012 FY | -1.32 Million SEK | -336.79% |
| 2011 FY | 560 Thousand SEK | -61.14% |
| 2010 FY | 1.44 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 82.614% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 104.485% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 104.485% |
| Arcoma AB | 4.66 Million SEK | 389.335% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 89.78% |
| BICO Group AB (publ) | -618.3 Million SEK | 97.819% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 134.334% |
| CellaVision AB (publ) | 167.05 Million SEK | 108.071% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 79.55% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 54.406% |
| C-Rad AB (publ) | 44.24 Million SEK | 130.474% |
| Duearity AB (publ) | -25.76 Million SEK | 47.665% |
| Dignitana AB (publ) | -15.02 Million SEK | 10.269% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 85.777% |
| Getinge AB (publ) | 3.81 Billion SEK | 100.354% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 80.301% |
| Iconovo AB (publ) | -45.77 Million SEK | 70.546% |
| Integrum AB (publ) | 6.51 Million SEK | 307.038% |
| Luxbright AB (publ) | -25.8 Million SEK | 47.749% |
| Mentice AB (publ) | -679 Thousand SEK | -1885.714% |
| OssDsign AB (publ) | -91.95 Million SEK | 85.338% |
| Paxman AB (publ) | 12.61 Million SEK | 206.847% |
| Promimic AB (publ) | -9.11 Million SEK | -47.872% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 92.008% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 75.003% |
| Sectra AB (publ) | 518.49 Million SEK | 102.6% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 79.43% |
| Senzime AB (publ) | -133.74 Million SEK | 89.919% |
| SpectraCure AB (publ) | -21.35 Million SEK | 36.851% |
| Stille AB | 44.95 Million SEK | 129.994% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 99.624% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 135.015% |